Impact of the SARS-CoV-2 pandemic on the survival of patients with high-grade glioma and best practice recommendations.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
16 02 2023
16 02 2023
Historique:
received:
06
07
2022
accepted:
10
02
2023
entrez:
16
2
2023
pubmed:
17
2
2023
medline:
22
2
2023
Statut:
epublish
Résumé
The severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has changed the clinical day-to-day practice. The aim of this study was to evaluate the impact of the pandemic on patients with high-grade glioma (HGG) as well as to derive best practice recommendations. We compared a multi-institutional cohort with HGG (n = 251) from 03/2020 to 05/2020 (n = 119) to a historical cohort from 03/2019 to 05/2019 (n = 132). The endpoints were outcome (progression-free survival (PFS) and overall survival (OS)) as well as patterns of care and time intervals between treatment steps. The median OS for WHO grade 4 gliomas was 12 months in 2019 (95% Confidence Interval 9.7-14.3 months), and not reached in 2020 (p = .026). There were no other significant differences in the Kaplan-Meier estimates for OS and PFS between cohorts of 2019 and 2020, neither did stratification by WHO grade reveal any significant differences for OS, PFS or for patterns of care. The time interval between cranial magnetic resonance imaging (cMRI) and biopsy was significantly longer in 2020 cohort (11 versus 21 days, p = .031). Median follow-up was 10 months (range 0-30 months). Despite necessary disease containment policies, it is crucial to ensure that patients with HGG are treated in line with the recent guidelines and standard of care (SOC) algorithms. Therefore, we strongly suggest pursuing no changes to SOC treatment, a timely diagnosis and treatment with short time intervals between first symptoms, initial diagnosis, and treatment, as well as a guideline-based cMRI follow-up.
Identifiants
pubmed: 36797335
doi: 10.1038/s41598-023-29790-8
pii: 10.1038/s41598-023-29790-8
pmc: PMC9933015
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2766Informations de copyright
© 2023. The Author(s).
Références
Neuro Oncol. 2020 May 05;:
pubmed: 32369601
Rep Pract Oncol Radiother. 2019 Jan-Feb;24(1):35-40
pubmed: 30337846
Brain Disord. 2021 Jun;2:100012
pubmed: 33997826
Eur Urol. 2020 Jun;77(6):663-666
pubmed: 32279903
Acta Oncol. 2020 Mar;59(3):320-323
pubmed: 31573367
CNS Oncol. 2020 Dec 1;9(4):CNS64
pubmed: 33112686
J Neurosurg. 2009 Jan;110(1):156-62
pubmed: 18847342
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Br J Neurosurg. 2018 Dec;32(6):628-630
pubmed: 29426231
Pain Med. 2020 Nov 7;21(7):1331-1346
pubmed: 32259247
Int J Surg. 2020 Jul;79:180-188
pubmed: 32454253
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
Nat Rev Clin Oncol. 2021 Mar;18(3):170-186
pubmed: 33293629
Cancer Manag Res. 2021 Jul 29;13:5875-5887
pubmed: 34349561
Front Oncol. 2019 Jul 17;9:620
pubmed: 31380272
Br J Neurosurg. 2015;29(4):520-3
pubmed: 25738427
Radiother Oncol. 2002 Sep;64(3):259-73
pubmed: 12242114
Lancet Oncol. 2017 Jun;18(6):e315-e329
pubmed: 28483413
World Neurosurg. 2020 Jan;133:e640-e645
pubmed: 31568907
JAMA. 2015 Dec 15;314(23):2535-43
pubmed: 26670971
BMC Infect Dis. 2022 Feb 10;22(1):140
pubmed: 35144556
J Am Coll Dent. 2014 Summer;81(3):14-8
pubmed: 25951678
Cochrane Database Syst Rev. 2019 Dec 24;12:CD013137
pubmed: 31873964
Neurosurgery. 2017 Nov 1;81(5):824-833
pubmed: 28541497
Sci Rep. 2020 Mar 18;10(1):4926
pubmed: 32188907
Lancet Oncol. 2014 Aug;15(9):e395-403
pubmed: 25079102
J Gastrointest Surg. 2020 Oct;24(10):2357-2373
pubmed: 32607860
J Craniomaxillofac Surg. 2020 May;48(5):521-526
pubmed: 32303420